Novo Nordisk to Acquire Akero Therapeutics for Up to $5.2 Billion
Akero shareholders will receive $54 per share initially, plus $6 per share contingent on U.S. regulatory approval of its EFX drug by June 30, 2031.
Source link
About The Author
